Clinical characteristics of patients and controls for liver samples
| Subject . | Pathology . | ALT (IU/liter) . | HBeAg . | Sex . | Age . |
|---|---|---|---|---|---|
| H1a | CHB mild fibrosis | 45 | NEG | Male | 31 |
| H2a | CHB mild fibrosis | 100 | POS | Male | 23 |
| H3a | CHB moderate fibrosis | 246 | POS | Male | 42 |
| H4ab | CHB cirrhosis | 498 | NEG | Male | 34 |
| H5a | CHB no fibrosis | 48 | NEG | Male | 43 |
| H6a | CHB mild fibrosis | 63 | NEG | Male | 43 |
| H7b | CHBd | 40 | - | Male | 60 |
| H8b | CHBd | 56 | - | Male | 66 |
| H9b | CHBd | 110 | - | Male | 56 |
| H10b | CHBd | 79 | - | Male | 44 |
| H11b | CHBd | 45 | - | Female | 48 |
| H12c | CHB cirrhosis | 31 | - | Male | 54 |
| H13c | CHB fibrosis | 67 | NEG | Male | 49 |
| H14c | CHB cirrhosis | 54 | NEG | Male | 53 |
| H15c | CHB cirrhosis | 47 | NEG | Male | 50 |
| H16c | CHB + hepatocellular carcinoma | 19 | NEG | Male | 61 |
| C1ab | Nonprimary liver carcinomae | 140 | N/A | Female | 34 |
| C2a | Nonprimary liver carcinomae | 26 | N/A | Female | 56 |
| C3ab | Cholangiocarcinoma | 41 | N/A | Female | 34 |
| C4a | Nonprimary liver carcinomae | 34 | N/A | Male | 60 |
| C5ab | Nonprimary liver carcinomae | 17 | N/A | Female | 67 |
| C6a | Nonprimary liver carcinomae | 209 | N/A | Male | 66 |
| C7b | Hepatitis C virus infection | 54 | N/A | Female | 41 |
| C8b | Nonprimary liver carcinomae | 30 | N/A | Female | 60 |
| C9b | Nonprimary liver carcinomae | 30 | N/A | Male | 54 |
| C10b | Nonalcoholic steatohepatitis | 108 | N/A | Female | 32 |
| C11c | Healthy transplant donor | - | N/A | Male | 56 |
| C12c | Alcoholic cirrhosis | 19 | N/A | Male | 63 |
| C13c | Primary sclerosing cholangitis | 138 | N/A | Female | 29 |
| C14c | Primary sclerosing cholangitis | 69 | N/A | Female | 60 |
| C15c | Primary sclerosing cholangitis | - | - | Female | - |
| Subject . | Pathology . | ALT (IU/liter) . | HBeAg . | Sex . | Age . |
|---|---|---|---|---|---|
| H1a | CHB mild fibrosis | 45 | NEG | Male | 31 |
| H2a | CHB mild fibrosis | 100 | POS | Male | 23 |
| H3a | CHB moderate fibrosis | 246 | POS | Male | 42 |
| H4ab | CHB cirrhosis | 498 | NEG | Male | 34 |
| H5a | CHB no fibrosis | 48 | NEG | Male | 43 |
| H6a | CHB mild fibrosis | 63 | NEG | Male | 43 |
| H7b | CHBd | 40 | - | Male | 60 |
| H8b | CHBd | 56 | - | Male | 66 |
| H9b | CHBd | 110 | - | Male | 56 |
| H10b | CHBd | 79 | - | Male | 44 |
| H11b | CHBd | 45 | - | Female | 48 |
| H12c | CHB cirrhosis | 31 | - | Male | 54 |
| H13c | CHB fibrosis | 67 | NEG | Male | 49 |
| H14c | CHB cirrhosis | 54 | NEG | Male | 53 |
| H15c | CHB cirrhosis | 47 | NEG | Male | 50 |
| H16c | CHB + hepatocellular carcinoma | 19 | NEG | Male | 61 |
| C1ab | Nonprimary liver carcinomae | 140 | N/A | Female | 34 |
| C2a | Nonprimary liver carcinomae | 26 | N/A | Female | 56 |
| C3ab | Cholangiocarcinoma | 41 | N/A | Female | 34 |
| C4a | Nonprimary liver carcinomae | 34 | N/A | Male | 60 |
| C5ab | Nonprimary liver carcinomae | 17 | N/A | Female | 67 |
| C6a | Nonprimary liver carcinomae | 209 | N/A | Male | 66 |
| C7b | Hepatitis C virus infection | 54 | N/A | Female | 41 |
| C8b | Nonprimary liver carcinomae | 30 | N/A | Female | 60 |
| C9b | Nonprimary liver carcinomae | 30 | N/A | Male | 54 |
| C10b | Nonalcoholic steatohepatitis | 108 | N/A | Female | 32 |
| C11c | Healthy transplant donor | - | N/A | Male | 56 |
| C12c | Alcoholic cirrhosis | 19 | N/A | Male | 63 |
| C13c | Primary sclerosing cholangitis | 138 | N/A | Female | 29 |
| C14c | Primary sclerosing cholangitis | 69 | N/A | Female | 60 |
| C15c | Primary sclerosing cholangitis | - | - | Female | - |